Articles and Blogs

Drug Prices

340B Moving Forward: Legislative and Executive Branch 340B Priorities for 2019-2020


Posted on April 19, 2019 in Health Law News

Published by: Hall Render

We continue to receive questions regarding the future of the 340B drug discount program (“340B Program”) now that its mid-term longevity is no longer in doubt. These include whether Congress will continue to focus on limiting the 340B Program’s scope as well as what effect, if any, broader efforts to reduce drug costs might... READ MORE

Tags: , , , , , , , , ,

CMS Proposes to Require Manufacturers to Disclose Drug Prices in TV Ads


Posted on November 21, 2018 in Health Law News

Published by: Hall Render

The Centers for Medicare & Medicaid Services (“CMS”) recently issued a proposed rule (“Proposed Rule”) that would require pharmaceutical manufacturers to disclose the list price for a typical course of treatment of prescription drugs and biologics covered by Medicare or Medicaid in direct-to-consumer television advertisements. This policy development comes just two months after the... READ MORE

Tags: , , , , ,

CMS Proposes Major Change to Medicare Part B Drug Payment System Introducing International Pricing Index Model


Posted on November 9, 2018 in Health Law News

Published by: Hall Render

The Centers for Medicare & Medicaid Services (“CMS”) Center for Medicare and Medicaid Innovation proposed to lower the cost of Medicare Part B outpatient prescription drugs by establishing their prices based on lower drug prices of other advanced industrial nations as compiled in an “international price index” (“IPI”) and changing the way the current drug... READ MORE

Tags: , , , , , , , , , , , ,